Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline Portfolio News / By Karina Tin Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline Read More »
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones Portfolio News / By Karina Tin ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones Read More »
NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients Portfolio News / By Karina Tin NGM Bio Announces First Participant Dosed in EMERALD Phase 2 Clinical Study of NGM120 for the Treatment of Hyperemesis Gravidarum (HG) in Pregnant Patients Read More »
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy Portfolio News / By Karina Tin Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy Read More »
Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology Portfolio News / By Karina Tin Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology Read More »
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates Portfolio News / By Karina Tin ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates Read More »
Nura Bio Expands Leadership Team with C-Suite Appointments Portfolio News / By Karina Tin Nura Bio Expands Leadership Team with C-Suite Appointments Read More »
Kenai Therapeutics Establishes Research Facility at Lilly Gateway Labs Portfolio News / By Karina Tin Kenai Therapeutics Establishes Research Facility at Lilly Gateway Labs Read More »
NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer Portfolio News / By Karina Tin NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer Read More »
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine Portfolio News / By Karina Tin Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine Read More »
